MedTrace Logo

Study of WPV01 in Healthy Subjects

NCT06205329 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2024-06-13

No results posted yet for this study

Summary

A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WPV01 and WPV01 Co-administrated With Ritonavir in Healthy Adult Subjects.

Conditions

  • Healthy Participants

Interventions

DRUG

WPV01 Dose 1-4

WPV01 Dose 1-4 or Placebo on day 1

DRUG

WPV01 Dose 5-8 and Ritonavir

WPV01 Dose 5-8 and Ritonavir or Placebo on day 1

DRUG

WPV01 Dose 9-12

WPV01 Dose 9-12 or Placebo from day 1 to day 6

DRUG

WPV01 Dose 13-15 and Ritonavir

WPV01 Dose 13-15 and Ritonavir or Placebo from day 1 to day 6

DRUG

WPV01 Dose 16

Cohort 1:WPV01 Dose 16 or Placebo (with high fat meal) Cohort 2:WPV01 Dose 16 or Placebo (fasted)

Sponsors & Collaborators

  • Westlake Pharmaceuticals (Hangzhou) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-03
Primary Completion
2023-03-11
Completion
2023-07-26

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06205329 on ClinicalTrials.gov